Skip to main content
RADX
NASDAQ Life Sciences

放射药物治疗公司的RAD202进入1期临床试验第三组，获得积极的安全推荐

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$4.47
Mkt Cap
$49.42M
52W Low
$3.496
52W High
$16.25
Market data snapshot near publication time

summarizeSummary

放射药物治疗公司宣布，其177Lu-RAD202（RAD202）资产已进入其1期'HEAT'临床试验第三组，用于治疗HER2阳性晚期实体瘤。这一进展是在数据安全和监测委员会（DSMC）提出积极推荐后实现的，允许将剂量提高到130mCi。这一消息凸显了放射药物治疗公司持续的临床开发，继最近有关其他管道资产如RAD 402和RAD 101的公告之后。对于一家小盘生物制药公司来说，在早期临床试验中推进一种药物，尤其是在获得积极的安全审查后，是一个重要的风险降低事件。它表明该药物在初始剂量下耐受性良好，并使其更接近潜在的疗效研究。投资者现在将监测1期剂量升级的进一步更新，公司计划在2026年底完成这一阶段。

在该公告发布时，RADX的交易价格为$4.47，交易所为NASDAQ，所属行业为Life Sciences，市值约为$4942万。 52周交易区间为$3.50至$16.25。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed RADX - Latest Insights

RADX
Apr 23, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
9
Radiopharm Theranostics Faces Short Cash Runway with 1.29 Quarters of Funding
Sentiment: Negative
View Wiseek Article
RADX
Apr 20, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Radiopharm Theranostics Reports Encouraging Initial Phase 1 Data for 177Lu-RAD202 in HER2+ Solid Tumors
Sentiment: Positive
View Wiseek Article
RADX
Apr 16, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Radiopharm Theranostics Completes Enrollment in Phase 2b Trial for Brain Metastases Diagnostic RAD 101
Sentiment: Positive
View Wiseek Article
RADX
Apr 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Radiopharm Theranostics' RAD202 Advances to Phase 1 Cohort 3 with Positive Safety Recommendation
Sentiment: Positive
View Wiseek Article
RADX
Apr 07, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Radiopharm Partners with Siemens Healthineers for RAD101 Phase 3 Clinical Supply
Sentiment: Positive
View Wiseek Article
RADX
Mar 27, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Radiopharm Theranostics Doses First Patient in Phase 1 Study for Advanced Prostate Cancer Drug RAD 402
Sentiment: Positive
View Wiseek Article
RADX
Mar 24, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
8
RAD 101 Phase 2b Interim Data Shows 90% Achievement of Primary Endpoint in Brain Metastases Trial
Sentiment: Positive
View Wiseek Article
RADX
Feb 27, 2026, 8:01 AM EST
Filing Type: 6-K
Importance Score:
8
Radiopharm Reports Strong Clinical Progress and Secures Substantial Funding, Extending Runway
Sentiment: Positive
View Wiseek Article
RADX
Feb 24, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
7
Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Trial for Novel Radiotherapeutic
Sentiment: Positive
View Wiseek Article
RADX
Jan 28, 2026, 7:03 AM EST
Filing Type: 6-K
Importance Score:
7
Radiopharm Theranostics Reports Promising Clinical Data Amidst Shortened Cash Runway
Sentiment: Neutral
View Wiseek Article